focus -WSS

focus

author：Wikipedia 2025-08-04 03:41:46 - browse：78274

A view of different flags of the European Union Members. -- first opinion coverage from STAT — Ronald Wittek, Pool Photo via AP

Today, the criteria used to assess the clinical value of new pharmaceuticals and medical devices varies widely across Europe, making it more challenging for biopharma companies to efficiently launch products in multiple countries and contributing to the disparities in access across the continent.

But change is on the horizon: In less than 15 months, the European Union will establish and begin to implement a standardized, pan-EU framework, which all 27 of member states will be required to use to assess the clinical evidence of newly submitted products or devices. A key pillar of the EU’s Regulation on Health Technology Assessment (HTA), the Joint Clinical Assessment (JCA) aims to establish a single, transparent process to reduce redundant practices and bring life science innovation faster to patients in Europe — no matter where they live.

In a longstanding problem in Europe, access to — and the availability of — medication varies across the member states. For example, in Germany, 87% of products approved by the European Medicines Agency (EMA) have full availability (the product gained access on the public reimbursement list without any restrictions to the patient population). In Poland, that figure drops to 8%, according to a report published by the European Federation of Pharmaceutical Industries. Meanwhile, there is a tremendous difference in the gap between an oncology therapy receiving marketing authorization and a formal positive reimbursement decision, ranging from an average of 86 days in Denmark to 981 days in Latvia.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： STAT's guide to the next generation of CAR

focus

WSS

Pfizer is about to make a big push in cancer. Will investors listen?

Death of patient in Alzheimer’s trial raises question of possible risks

5 ways to address the shortage of health care workers

Mifepristone protocols being wielded by pill's opponents in Supreme Court case

#NeedHerScience: shining a light on gender disparities in medicine

Virtual repurposing can help discover new uses for existing drugs

hotspot

focus

hotspot

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Gene therapy has helped boys walk. Can scientists keep it that way?

Walensky prepares to leave CDC — and Congress — behind

'Vaccine

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why we need to separate burnout from moral injury in health care

New air purifier tech could be key to improving indoor air quality

Ask STAT: What do you want to know about ChatGPT in medicine?

The high cost of giving birth even with insurance

CDC panel: People 65 and older should get a Covid spring booster shot

focus

There should be a 'Moonshot' or 'Warp Speed' for rare diseases

Covid overtakes 1918 Spanish flu as deadliest disease in U.S. history

Readout Newsletter: Beam, Prozac, "TechBio" and more

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

CDC panel: People 65 and older should get a Covid spring booster shot

#NeedHerScience: shining a light on gender disparities in medicine

entertainment

knowledge

focus

focus